SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices surge amid reported tanker attacks and supply risks around the Strait of Hormuz, alongside concerns about Saudi and Russian energy infrastructure. Traders are split between betting on further gains from geopolitical disruption and warning that prices look extended and could retreat if diplomacy or supply relief eases those fears.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a volatile tech rebound, with traders split over whether repeated V-shaped recoveries reflect durable dip-buying or a bull trap. Rising oil prices tied to Middle East tensions and doubts about AI infrastructure spending weigh on sentiment, while upcoming megacap earnings are seen as a test for the bounce.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops warrant-expiration deadline is dominating discussion: holders are weighing whether the shares can reach the warrants exercise price before they expire, while traders debate whether they will lapse worthless or be extended. The uncertainty has fueled frustration over the recent pullback and Cohens actions, alongside bullish speculation that he could still provide a catalyst and bearish views that expiration would remove potential dilution.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

A prolonged post-IPO selloff is dominating discussion, with traders citing upcoming lockup expirations and insider share sales as added supply pressure, alongside a TD Cowen price-target cut and concerns about valuation, growth, and customer concentration. Bears see further downside risk, while some bulls argue the shares are oversold and Cerebrass AI-chip technology offers long-term potential.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

CIFR is drawing attention after a steep selloff that traders widely blame on its convertible-note financing and expected share dilution, alongside broader weakness in AI/data-center stocks and concerns about debt and financing costs. The reaction is sharply divided: many holders criticize management and fear further losses, while some see the decline as an oversold pullback and remain bullish on its AI infrastructure contracts.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Hot inflation readings and elevated Treasury yields are weighing on rate-sensitive small caps, with traders focused on Fed tightening risks and IWMs technical weakness. The discussion is split between bearish bets on further declines and buyers looking for an oversold bounce near support.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock to Sell, citing long commercialization timelines and a lack of firm customer commitments; traders debate whether the selloff reflects those execution risks or is an overreaction, with some bulls still backing the long-term nuclear-power thesis. The decline also fits broader weakness in speculative nuclear stocks.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp AI-infrastructure selloff and a relief bounce, with traders split on whether the rebound signals stabilization or another short-lived rally. Concerns about neocloud financing and capital spendingheightened by CoreWeaves debt worriescompete with the bullish view that Nebius is better positioned and could capture demand from struggling providers.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff is being tied mainly to concerns about its heavy debt, financing costs and ability to fund AI infrastructure expansion, amid broader weakness in neocloud stocks. Bears warn of dilution or default, while bulls cite its contracted backlog, Nvidia ties and ARKs buying; the Goldman upgrades failure to sustain a rally underscores the divide.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is being linked by traders to weakening support for Trump ahead of the midterms, with many voicing bearish views and pointing to Truth Socials limited engagement and the companys weak business fundamentals. A smaller bullish contingent views the selloff as a buying opportunity and cites the planned TAE Technologies merger.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A rotation into defensive healthcare amid weakness in tech and AI is drawing attention to Lillys relative strength and recent share-price momentum, with traders also watching its obesity-drug business ahead of earnings. Sentiment is mostly bullish, though some see the move as vulnerable to profit-taking and question whether the stocks valuation already reflects its growth prospects.

SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years 

Equity

Executive severance changes from June and Sellas’ sizable ASH conference booth have fueled deal speculation.

Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts

In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -1.33% move from the previous day.

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market

Key PointsRegeneron's leading weight-loss candidate could offer patients an option with fewer side effects...

How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?

LLY's surging Mounjaro and Zepbound sales, alongside Foundayo's expanding market access, strengthen its GLP-1 growth momentum ahead of Q3 results.

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to...

SLS Stock Logs Worst Week In Over A Month: Retail Bulls Bet ASH Embargo Is Keeping Regal Results Under Wraps 

Sellas’s 600-square-foot ASH booth also fueled speculation about a potential clinical update.

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) CongressPR NewswireINDIANAPOLIS, Oct. 18, 2026 First Phase 1...

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher

Key PointsEli Lilly could continue to dominate the weight-loss market thanks to medicines like Foundayo and retatrutide...

Lilly’s Foundayo Pill Gets European Regulatory Backing – LLY Stock Heads For Best Week In Nearly Four Months

European Medicines Agency’s advisory committee recommended approval of its once-daily weight-loss pill, Foundayo.


Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too?

Key PointsThe sale has nothing to do with the stock's potential, however...

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Bullish Sentiment

<ul class="summary-bullets"><li>CEO Angelos Stergiou marked Sellas’ 15th anniversary, pointing to its “next chapter” with GPS and SLS009.</li><li>Retail investors floated $40 billion-$120 billion valuation scenarios and share-price predictions ranging from $100 to $540.&nbsp;</li><li>Investors await Regal’s final-analysis trigger of 80 deaths, following Sellas’ disclosure of 78 events as of May 11.</li></ul>Retail investors in Sellas Life Sciences (SLS) are floating multibillion-dollar buyout scenarios and steep share-price gains after CEO Angelos Stergiou marked the company’s 15th anniversary with a post about its “next chapter.”<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped 5% on Monday to $10.49, snapping three straight losing sessions.&nbsp;<h2 class="st-heading-2">Sellas CEO Points To ‘Best Chapters’ Ahead</h2>In his LinkedIn post, Stergiou reflected on Sellas’ growth from a private startup into a public biotech advancing investigational cancer treatments GPS and SLS009.“Reaching 15 years isn't just about celebrating our history; it is about stepping into our next chapter with even greater focus, drive, and resolve,” he said. He acknowledged past setbacks and thanked shareholders, employees and trial participants, while reaffirming the company’s commitment to patients.“Our mission remains deeply personal, and our promise to the patients we aim to serve is steadfast. We look forward, God willing, to the best chapters that are still to be written with GPS and SLS009,” he added.<h2 class="st-heading-2">SLS Retail Floats Multibillion-Dollar Buyout Scenarios</h2>On Stocktwits, retail sentiment for SLS slipped to ‘bearish’ from ‘bullish’ levels a day ago amid a 258% jump in 24-hour message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_725c1f1d42.png" alt="sls ss.png" width="633" height="343"><figcaption>SLS sentiment and message volume as of October 19 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Reformed_MMAT_investor/message/666881029">said</a>: “My opinion, Dr. Stergiou’s message was a master-class at reassuring EVERYONE that all is well.”A user<a href="https://stocktwits.com/Gebinator/message/666869438"> also&nbsp;floated</a> a minimum $40 billion valuation. Another user<a href="https://stocktwits.com/55X_ROI_Q1_2026/message/666882686">&nbsp;argued</a> for a $50 billion valuation, calling a $247-per-share figure. A separate user<a href="https://stocktwits.com/vlucky16/message/666866929">&nbsp;proposed</a> a $120 billion buyout scenario and also predicted a share price of $540-plus.Across bullish share-price predictions, including scenarios tied to clinical results, targets ranged from $100 to over $540. Discussing buyout news in case of favorable data, one user&nbsp;<a href="https://stocktwits.com/AIALuckyDog/message/666879536">said</a>: “If BO news post good data then there’s no stopping this beast (really no explanation required as it could go full berserker mode).” BO means buyout.Another user challenged the lofty valuations and&nbsp;<a href="https://stocktwits.com/noviceEve/message/666855368">said</a>: “I will be so glad to get out of this ticker when it hits $15 again.”<h2 class="st-heading-2">Retail Searches Filings, Conference Plans For Clues</h2>The CEO’s message comes as investors have been&nbsp;searching for potential deal signals in recent months. In June, a filing disclosed changes to executive severance arrangements, including lump-sum payment provisions for Stergiou.For CFO John Burns and chief development officer Dragan Cicic, qualifying departures within one month before or one year after a change of control would trigger 15 months of salary, the annual target bonus, up to 18 months of health-coverage reimbursements and full vesting of unvested equity.&nbsp;Sellas’ conference plans have provided another talking point. The company is listed at Booth 138, with a 20-by-30-foot space, for the Dec.12- Dec.15 American Society of Hematology (ASH) meeting in New Orleans. Major exhibitors include Eli Lilly, Pfizer, Merck, AbbVie and Bristol Myers Squibb. The booth size has fueled speculation about a partnership or acquisition.<h2 class="st-heading-2">Sellas Regal Trial And SLS009 Data In Focus</h2>Currently, investors are awaiting data from Sellas’ two lead programs. The Phase 3 Regal trial is testing GPS, an immunotherapy targeting WT1, in acute myeloid leukemia (AML) patients who achieved a second complete remission following salvage treatment. Its final-analysis process is triggered by 80 deaths. Sellas reported 78 events as of May 11. Reaching 80 precedes database lock, data review and analysis before results are disclosed.&nbsp;The company also expects fourth-quarter topline data from its 80-patient Phase 2 SLS009 study in newly diagnosed AML, including patients with early resistance to azacitidine and venetoclax. SLS009 is also being explored in pancreatic cancer. Preclinical findings from last month showed 17.9% apoptosis (programmed cell death) in a patient-derived tumor model resistant to Daraxonrasib, versus 2.8% with Daraxonrasib alone. Combining the drugs raised apoptosis to 36.5% and necrosis to 30.6%.&nbsp;SLS stock has surged 178% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avgo-stock-10-year-docomo-deal-retail-on-edge-ceo-ai-casino-remarks/cZxqiudRBuJ">AVGO Stock Edges Up Overnight After 10-Year Docomo Deal, But Retail Stays On Edge Over CEO’s AI ‘Casino’ Remarks&nbsp;</a>

Representative Image (Photo credit: Getty Images)

SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years

Abbvie Inc

Bristol-Myers Squibb Co.

Merck & Co Inc

Pfizer Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

$AMD

$SHOP

$UBER

$LLY

$AMD, $SHOP, $UBER, and $LLY are four of the most searched and talked-about stocks among retail investors this morning. Which are you most bullish on? Drop your reasoning in the comments.

Which of these trending stocks are you most bullish on for the next 5 years - $AMD, $SHOP, $UBER, or $LLY? 
 
Explain why in the comments.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$5.65	--	--	N/A
Q2 '26	$6.01	$8.38	39.53%	BEAT
Q1 '26	$6.97	$8.55	22.71%	BEAT
Q4 '25	$6.91	$7.54	9.10%	BEAT
Q3 '25	$5.69	$7.02	23.33%	BEAT

Feed

News

Sentiment

Earnings

NewFutures

Fundamentals

Info

LLY Earnings

Upcoming Earnings: Q3 '26

Historical Earnings